References
- Kim EJ, Hess S, Richardson SK, . Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 2005;115:798–812.
- Dummer R, Urosevic M, Kempf W, . Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides. Dermatology 2003;207:116–118.
- Suchin KR, Junkins-Hopkins JM, Rook AH. Treatment of stage IA cutaneous T-cell lymphoma with topical application of the immune response modifier imiquimod. Arch Dermatol 2002;138:1137–1139.
- Spaner DE, Miller RL, Mena J, . Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod. Leuk Lymphoma 2005;46:935–939.
- Deeths MJ, Chapman JT, Dellavalle RP, . Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. J Am Acad Dermatol 2005;52:275–280.
- Wysocka M, Newton S, Benoit BM, . Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-gamma enhances production of interleukin-12. Clin Lymphoma Myeloma 2007;7:524–534.
- Wysocka M, Benoit BM, Newton S, . Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and Il-15. Blood 2004;104:4142–4149.
- Kim YH, Girardi M, Duvic M, . Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol 2010;63:975–983.
- Schon MP, Schon M. Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod. Apoptosis 2004;9:291–298.
- Chiron D, Bekeredjian-Ding I, Pellat-Deceunynck C, . Toll-like receptors: lessons to learn from normal and malignant human b cells. Blood 2008;112:2205–2213.
- Li VW, Li WW, Talcott KE, . Imiquimod as an antiangiogenic agent. J Drugs Dermatol 2005;4:708–717.
- Gramling MW, Church FC. Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment. Thromb Res 2010;125:377–381.
- Miyazawa M, Takahashi S, Kawaguchi H, . Low expression of adhesion molecules in a case of cutaneous T-cell lymphoma. J Dermatol 1995;22:659–664.
- Lopez-Lerma I, Estrach MT. A distinct profile of serum levels of soluble intercellular adhesion molecule-1 and intercellular adhesion molecule-3 in mycosis fungoides and sezary syndrome. J Am Acad Dermatol 2009;61:263–270.
- Wilcox RA, Wada DA, Ziesmer SC, . Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. Blood 2009;114:2936–2944.
- Sarris AH, Daliani D, Ulmer R, . Interferon-inducible protein-10 and the pathogenesis of cutaneous T-cell lymphomas. Leuk Lymphoma 1996;24:103–110.
- Urosevic M, Willers J, Mueller B, . HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood 2002;99:609–617.
- Hara T, Tsurumi H, Takemura M, . Serum-soluble Fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin's lymphoma. Am J Hematol 2000;64:257–261.